This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will Vapotherm Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Vapotherm
The Zacks Analyst Blog Highlights: Vapotherm, Inogen and Invacare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vapotherm, Inogen and Invacare
Vapotherm (VAPO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Stocks in Focus as Coronavirus Boosts Medical Oxygen Demand
by Manaswita Ghosh Dutta
Oxygen therapy has emerged as a necessity for COVID-19 patients.
Vapotherm (VAPO) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Vapotherm (VAPO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vapotherm (VAPO) delivered earnings and revenue surprises of 16.67% and 6.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Vapotherm (VAPO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health's Selling Seasons Strong, Omnicare Arm Upsets
by Zacks Equity Research
CVS Health's (CVS) 2020 PBM selling season remains strong with gross new business and net new business wins.
Hologic Posts Solid Preliminary Q1 Sales, Revises Buyback Plan
by Zacks Equity Research
Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.
Thermo Fisher Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about maintaining its growth momentum on several recent developments.
Medtronic's Neurostimulator DBS System Receives CE Mark
by Zacks Equity Research
Medtronic's (MDT) Percept PC neurostimulator DBS system, with BrainSense technology, receives the CE Mark, thus clearing the way for the treatment of various neurologic disorders in the EU.
Medtronic (MDT) Buys Stimgenics, To Present New Trial Results
by Zacks Equity Research
Medtronic (MDT) acquires Stimgenics to integrate DTM therapy in its pain therapies segment. It will also present trial results favoring the therapy at the upcoming NANS meeting.
Neogen Expands in South America With Productos Acquisition
by Zacks Equity Research
Neogen (NEOG) expands operations in South America by acquiring its food safety diagnostics distributor partner that operates in Argentina and Uruguay.
Here's Why You Should Hold on to Zimmer (ZBH) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Zimmer (ZBH) on its stellar segmental performance in Q3.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on its stellar segmental performance in Q3.
Hill-Rom Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Hill-Rom (HRC) is optimistic about maintaining its growth momentum on several recent developments.
Amedisys Completes Asana Hospice Acquisition, Expands Network
by Zacks Equity Research
Amedisys (AMED) closes Asana takeover to strengthen its hospice care network.
Zacks.com featured highlights include: ACM, K12, Vapotherm, Equity Commonwealth and Columbus McKinnon
by Zacks Equity Research
Zacks.com featured highlights include: ACM, K12, Vapotherm, Equity Commonwealth and Columbus McKinnon
New Analyst Coverage Puts Spotlight on These 5 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.